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Trials of peroxisome proliferator-activated receptor (PPAR) agonists have shown mixed results for cardiovascular prevention. Fi-
brates are PPAR-α agonists that act primarily to improve dyslipidemia. Based on low- and high-density lipoprotein cholesterol
(LDL and HDL) eﬀects, gemﬁbrozil may be of greater cardiovascular beneﬁt than expected, fenoﬁbrate performed about as ex-
pected, and bezaﬁbrate performed worse than expected. Increases in both cardiovascular and noncardiovascular serious adverse
events have been observed with some ﬁbrates. Thiazolidinediones (TZDs) are PPAR-γ agonists used to improve impaired glucose
metabolism but also inﬂuence lipids. Pioglitazone reduces atherosclerotic events in diabetic subjects, but has no net cardiovascular
beneﬁt due to increased congestive heart failure risk. Rosiglitazone may increase the risk of atherosclerotic events, and has a net
harmful eﬀect on the cardiovascular system when congestive heart failure is included. The primary beneﬁt of TZDs appears to be
the prevention of diabetic microvascular complications. Dual PPAR-α/γ agonists have had unacceptable adverse eﬀects but more
selective agents are in development. PPAR-δ and pan-agonists are also in development. It will be imperative to prove that future
PPAR agonists not only prevent atherosclerotic events but also result in a net reduction on total cardiovascular events without
signiﬁcant noncardiovascular adverse eﬀects with long-term use.
Copyright © 2008 Jennifer G. Robinson. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Drugs aﬀecting peroxisome proliferator-activated receptors
(PPARs) are of intense interest for regulating disorders of
glucose and fatty acid metabolism [1].As an end-stage man-
ifestation of insulin resistance and glucose intolerance, dia-
betes confers a 2-to-8-fold higher risk of coronary heart dis-
ease (CHD), stroke, and mortality [2].Impaired glucose tol-
erance also contributes to the development of atherogenic
dyslipidemia,whichischaracterizedbyelevatedtriglycerides,
low high-density lipoprotein (HDL) cholesterol, small dense
low-density lipoprotein (LDL) cholesterol, and elevated LDL
particle number. Independent of insulin resistance and glu-
cose levels, atherogenic dislipidemia imparts a risk for CHD
at least equal to that of the well-characterized risk of isolated,
moderate hypercholesterolemia [3].
Agonists of PPAR-α and PPAR-γ have been evaluated for
the long-term prevention of cardiovascular events. Fibrates
are low-aﬃnity PPAR-α agonists which lower triglycerides
by increasing lipolysis and β-oxidation of fatty acids [4]. Fi-
brates also mildly raise HDL and, in some cases, lower LDL.
Pharmacologic activation of PPAR-γ also lowers triglyceride
levels by promoting fatty acid storage [5]. The main beneﬁts
of PPAR-γ agonists, however, are improvements in glucose
homeostasis. Thiazolidinediones (TZDs), or glitazones, are
primarily PPAR-γ agonists that promote fatty acid oxidation
and insulin sensitivity in liver and muscle [1]. These bene-
ﬁcial eﬀects appear to be mediated, at least in part, through
inhibition of the release of signaling molecules from adipose
tissue that promote insulin resistance, including inﬂamma-
tory factors such as tumor necrosis factor-α (TNF-α)a n d
resistin, and stimulating the release of adiponectin. PPAR-γ
agonism may additionally lower plasma glucose levels via de-
creasedhepaticglucoseproduction.DualPPAR-αandPPAR-
γ agonists have also been developed. Drugs aﬀecting the
more recently identiﬁed PPAR-δ (also called β) are in the
early stages of development. PPAR-δ is also a powerful reg-
ulator of fatty acid catabolism and energy homeostasis and
has been shown to prevent weight gain, dyslipidemia, and
fatty liver in animals fed high-calorie diets [6, 7]. Given the
central role of PPARs in lipid and glucose metabolism, has
thepromiseofPPARmodulationtranslatedintoasigniﬁcant2 PPAR Research
cardiovascular risk reduction beneﬁt from these agents? Sev-
eral recently completed large trials addressing this question
have had mixed results.
2. PPAR-α AGONISTS: FIBRATES
Randomized,placebo-controlledtrialshaveshownthatgem-
ﬁbrozil signiﬁcantly reduces the risk of CHD in primary and
secondaryprevention populations ofdyslipidemic men,with
evidence of a trend toward a decrease in stroke (Table 1)
[8, 9]. Less robust results were observed for bezaﬁbrate in
subjects with CHD, and for fenoﬁbrate in subjects with dia-
betes [10, 11]. The cardiovascular beneﬁts of gemﬁbrozil ap-
pear to be greater than expected from changes in LDL and
HDL. In the Veterans Aﬀairs HDL Intervention Trial (VA-
HIT),a>20%reductioninCHDandstrokeoccurreddespite
noeﬀectonLDLandonlya6%increaseinHDL.Thisreduc-
tion in risk was also found to be independent of changes in
triglycerides and was largely attributable to the use of gem-
ﬁbrozil itself [12]. The only other long-term trial with gem-
ﬁbrozil, the Helsinki Heart Study, also reported a greater re-
duction in cardiovascular risk than have been expected on
the basis of changes in LDL and HDL. Figure 1 is based on
the assumption that each 1% decrease in LDL and each 1%
increase in HDL are additive and would therefore result in
a 2% reduction in cardiovascular risk. Data supporting this
assumption comes from clinical trials where each 1% reduc-
tion in LDL results in approximately a 1% reduction in the
risk of CHD and stroke, regardless of the method by which
LDL is lowered [13]. The VA-HIT study found that a 5mg/dl
increase in HDL (16%) reduced risk by 11% [12]. This is
consistent with epidemiologic data in which each 1mg/dl
(0.03mmol, or about a 2-3%, depending on baseline HDL
level) increase in HDL is associated with a 2–4% reduction
in the risk of CHD events, independent of LDL-C cholesterol
levels [14]. It is assumed, but not proven, that raising HDL
results in risk reduction additive to that of lowering LDL.
In contrast to the 2 trials with gemﬁbrozil, the 11% re-
ductionincardiovascularriskobservedintheFenoﬁbrateIn-
tervention and Event Lowering in Diabetes (FIELD) trial was
similar to that expected (about 12%) from average changes
in LDL (−9%) and HDL (+3%) between 4 months and the
endofthestudy(Figure 1;Table 2)[11].Themidpointofthe
studywaschosenduetocrossovertostatintreatmentinboth
treatment arms. By the end of the trial, 17% of the placebo
group and8% of the fenoﬁbrategroupstarted lipid-lowering
therapy, mainly with statins. As a consequence, the lipid pa-
rameters for the 2 treatment groups became more similar
over time.
The Bezaﬁbrate Infarction Prevention (BIP) study
showed a nonsigniﬁcant reduction in cardiovascular events
of only 9% despite greater changes in LDL and HDL than
those observed in FIELD or VA-HIT (Table 2)[ 8, 10, 11].
Indeed, bezaﬁbrate performed substantially worse than ex-
pected from the LDL and HDL changes (Figure 1), suggest-
ing that bezaﬁbrate may have vascular toxicity that counter-
acts its beneﬁcial lipid changes. This may be due to bezaﬁ-
brateactingasapan-PPARactivator,asdiscussedbelow[15].
It has been argued that the lesser cardiovascular bene-
ﬁt observed in FIELD and BIP was due to inclusion of less
dyslipidemic subjects than in the gemﬁbrozil trials. A post
hoc subgroup analysis of BIP found a signiﬁcant (40%) re-
duction in CHD in those with triglycerides ≥200mg/dl [10].
VA-HIT found a similar trend toward increasing risk re-
duction with triglyceride levels ≥180mg/dl [12]. In FIELD,
fenoﬁbrate, there were similar with reductions in cardiovas-
cular risk in subjects with triglycerides less than and greater
than 150mg/dl. On the other hand, the Diabetes Atheroscle-
rosis Intervention Study (DAIS) found that fenoﬁbrate re-
duced angiographic progression of coronary atherosclerosis
in a more markedly hypertriglyceridemic diabetic popula-
tion [triglycerides 229mg/dl (2.59mmol/L); HDL 39mg/dl
(1.01mmo/L); LDL 130mg/dl (3.38mmol/L)] [16]. How-
ever, when looking at the mean lipid levels across the stud-
ies, the case is less clear. The triglyceride levels in FIELD
(172mg/dl) were similar to those in the Helsinki Heart
Study (178mg/dl), but somewhat higher than in VA-HIT
(160 mg/dl) and BIP (145mg/dl) (Table 2). HDL levels were
markedly lower in BIP (35 mg/dl) and in VA-HIT (32mg/dl)
than in either FIELD (43mg/dl) or the Helsinki Heart Study
(47mg/dl). Taken as a whole, these ﬁndings may suggest that
gemﬁbrozil may have a greater impact on cardiovascular risk
than fenoﬁbrate, regardless of the population studied.
Also of concern, some ﬁbrates used alone may poten-
tially increase the risk of cardiovascular and noncardio-
vascular mortality, and of serious adverse events (Table 1).
Cloﬁbrate, the earliest ﬁbrate studied, is rarely used due
to a consistent increase in mortality when compared to
placebo, which occurred despite a substantial reduction in
CHD events [17, 18]. In BIP, more cases of CHD mortal-
ity were reported for the bezaﬁbrate group compared to
placebo, although the diﬀerence was not statistically signif-
icant (Table 1)[ 10]. In FIELD, there were also more adverse
events and deaths among those receiving fenoﬁbrate com-
pared to placebo [11]. The reduction in nonfatal coronary
events and stroke in FIELD was counterbalanced by an 11%
increase in cardiovascular deaths (due to a 19% increase in
CHD death) and total mortality that did not reach statisti-
cal signiﬁcance. The excess in deaths was due to a variety
of causes: sudden cardiac death (70 versus 54, resp.), heart
failure (13 versus 11), noncoronary cardiac (8 versus 4), and
pulmonaryembolism(4versus1,P = .22).Althoughalower
rate of cardiac events in the statin-treated placebo group is
one possible explanation for the unexpected increase in car-
diac deaths, a 30% excess of sudden death in the fenoﬁ-
brate group is hard to explain if only an excess 9% of the
placebo group received a statin. In contrast, fewer deaths
occurred in the secondary-prevention population studied
in the Veterans Aﬀairs HDL Intervention Trial (VA-HIT)
and in the primary-prevention Helsinki Heart Study [8, 9].
The secondary-prevention component of the Helsinki Heart
Study reported anonsigniﬁcant increase inCHD deathswith
gemﬁbrozil compared to placebo in a much smaller sam-
ple (N = 628, HR 2.2% (95% CI 0.94–5.05)) [19]. It is im-
portant to note that no excess of harm has emerged in any
statin trial. A meta-analysis of statin therapy in over 90,000
participants in 14 event trials found a 19% reduction inJennifer G. Robinson 3
Table 1: Selected morbidity and mortality outcomes in large, long-term ﬁbrate trials. CHD = coronary heart disease, CVD = cardiovascular
disease, MI = myocardial infarction, NR = not reported, ns = reported as “not signiﬁcant,” RR = Crude relative risk calculated form reported
number of events; hazard ratio was not reported.
Event rates
Study treatment Nonfatal MI CHD
mortality
Nonfatal
MI or CHD
death
Total stroke Cancer Total
mortality
Hospitalized
CHF
Helsinki Heart [9]
Mean F/U 5.0 years
Primary prevention
Dyslipidemia
High LDL
Placebo 3.5% 0.64% 4.1% NR 1.3% 2.1%
N = 2030
Gemﬁbrozil 2.2% 0.53% 2.7% NR 1.5% 2.2%
N = 2051
Hazard ratio
(95% CI)
RR 0.63 RR 0.83 0.66 NR RR 1.15 RR 1.05
P < .02 p = NR P < .02 p = NR p = NR
VA-HIT [8]
Mean F/U 5.1 years
CHD
HDL < 40mg/dl
LDL < 140mg/dl
Placebo 14.5% 9.3% 21.7% 6.0% 10.9% 17.4% 13.3%
N = 1267
Gemﬁbrozil 11.6% 7.4% 17.3% 4.6% 9.9% 15.7% 10.6%
N = 1264
Hazard ratio
(95% CI)
0.77 0.78 0.78 0.75
RR 0.91
0.89 0.78
(0.62–0.96) (0.59–1.02) (0.65–0.93) (0.53–1.06) (0.73–1.08) (0.62–0.98)
P < .02 P=.07 P=.006 P=.10 P=.23 P=.04
BIP[10]
Noncardiac death Mean F/U 6.2 years
CHD
Dyslipidemia
Placebo 11.2% 5.7% 15.0% 5.0% 5.9% 4.2%
N = 1542
Bezaﬁbrate N = 1548 9.7% 6.1% 13.6% 4.6% 5.5% 4.3%
Hazard ratio
(95% CI)
0.87 RR 1.07 0.91 RR 0.92 RR 0.93 RR 1.02
P=.18 P=.61 P=.26 P = .66ns P=.87
FIELD [11]
Laser
therapy
Albuminuria
not
progressing/
regressing
Mean F/U 5 years
Type 2 diabetes
Dyslipidemia
Low LDL
Placebo 4.2% 1.9% 6% 3.6% 8% 6.6% 5.2%
n = 4900
Fenoﬁbrate 3.2% 2.2% 5% 3.2% 8% 7.3% 3.6%
N = 4895
Hazard ratio
(95% CI)
0.76 1.19 0.89 0.90 1.11 0.70
RR 1.15
P=.002 (0.62–0.94) (0.90–1.57) (0.75–1.05) (0.73–1.12) RR 1.0 (0.95–1.29) (0.58–0.85)
P=.01 P=.22 P=.16 P=.36 P=.18 P=.00034 PPAR Research
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Figure 1: Approximate expected cardiovascular (CVD) risk reduction from percent changes in LDL and HDL versus observed percent
reduction in coronary heart disease (CHD) or CVD. Above the slope = 1 line, CVD risk reduction was worse than expected based on lipid
changes; below the slope = 1 line, CVD risk reduction was greater than expected based on the lipid changes.
CHD mortality and a 12% reduction in all-cause mortality
[20].
Although more malignancies were initially reported with
cloﬁbrate and gemﬁbrozil in 5-year primary-prevention tri-
als, with long-term followup there were no signiﬁcant in-
creases in cancer incidence or mortality with gemﬁbrozil,
even with followup as long as 18 years in the Helsinki Heart
Study [8, 21, 22]. Cancer incidence was similar for both the
fenoﬁbrate and placebo groups (8%) in FIELD [11].
Also of concern in FIELD, cardiovascular events, includ-
ing revascularizations, were signiﬁcantly reduced only in
those without previous cardiovascular disease and in those
<65 years of age (19% and 20%, resp.; P<. 005), with no
beneﬁt (0%) observed in those with previous cardiovascu-
lar disease or who where ≥ age 65 years at baseline. These
ﬁnding are in clear contradiction to the ﬁndings of the VA-
HIT study where men with both diabetes and CHD experi-
enced a 32% (95% CI 12–47, P = .004) reduction in cardio-
vascular events from gemﬁbrozil treatment [23]. The anal-
ysis has not been published to determine whether the ex-
planation for the FIELD ﬁndings lies in the higher rate of
crossover to other lipid-treatments in those with previous
cardiovascular disease. In those with previous cardiovascu-
lar disease, 23% of the placebo group and 14% of the fenoﬁ-
brate group crossed over to lipid-lowering therapy. In com-
parison, in those without previous cardiovascular disease,
16% of placebo and 7% of fenoﬁbrate groups crossed over
to statin therapy. On-treatment lipid values of the various
groups were not reported so it is diﬃcult to estimate whether
the lack of beneﬁt in those with previous cardiovascular dis-
ease and those ≥ age 65 years was due to crossover to active
t r e a t m e n to rt oo t h e rf a c t o r s .
In FIELD, the fenoﬁbrate group also experienced a non-
signiﬁcant increase in deep venous thrombosis [67 (1.4%)
versus 48 (1.0%); P = .74)]. No clear explanations for the
nonsigniﬁcant higher rates of sudden death, venous throm-
bosis, and pulmonary embolism in FIELD are readily appar-
ent. It is not known whether the increased risk of thrombo-
sis was due to higher homocysteine levels in the fenoﬁbrate
group. Gemﬁbrozil may raise homocysteine levels less thanJennifer G. Robinson 5
Table 2: Selected laboratory data from ﬁbrate endpoint trials.
Mean baseline level (mg/dL (mmol/L)) Percent diﬀerence between treatment groups
Helsinki Heart [76]
Gemﬁbrozil versus placebo
1 year 3 years 5 years
Total cholesterol 269 (6.98) −11% −10% −9%
LDL 189 (4.90) −11% −10% −9%
HDL 47 (1.22) 11% 10% 7%
Triglycerides 178 (2.01) −39% −37% −33%
Non-HDL 222 (5.76) −15% −14% −13%
VA-HIT [12]
Gemﬁbrozil versus placebo
1 year
Total cholesterol 175 (4.53) −4%
LDL 112 (2.90) 0%
HDL 32 (0.83) 6%
Triglycerides 160 (1.81) −31%
BIP [10]
Bezaﬁbrate versus placebo
1 year
Total cholesterol 212 (5.49) −5%
LDL 148 (3.83) −7%
HDL 34.6 (0.90) 18%
Triglycerides 145 (1.64) −21%
FIELD [11]
Fenoﬁbrate versus placebo
4 months End-of-study
Total cholesterol 194 (5.04) −11% −7%
LDL 119 (3.07) −12% −6%
HDL 42.5 (1.10) 5% 1%
Triglycerides 172 (1.94) −29% −22%
fenoﬁbrate [24]. It is not known whether the increased ho-
mocysteine levels resulted from the reversible increases in
creatinine observed with fenoﬁbrate, and also bezaﬁbrate,
and less commonly gemﬁbrozil [25]. Fenoﬁbrate is known
to raise homocysteine through a PPAR-α mediated mecha-
nism [26]. Folic acid appears to lower fenoﬁbrate-induced
homocysteine elevations [27]. However, since clinical trials
of folic acid supplementation to lower homocysteine have
not demonstrated a reduction in cardiovascular events [28],
the clinical importance of fenoﬁbrate-induced homocysteine
elevations remains to be established.
Noris it clearthatthe increasein creatinine levelswithﬁ-
brates increases cardiovascular risk since preliminary studies
have shown that fenoﬁbrate increases creatinine production
rather than decreasing the glomerular ﬁltration rate [25, 29].
In FIELD, progression of proteinuria and renal failure were
less frequent in those receiving fenoﬁbrate (Table 2)[ 11, 25].
No cases of renal failure were reported with gemﬁbrozil in
the Helsinki Heart Study or in VA-HIT [8, 9].
All ﬁbrates are known to increase biliary cholesterol sat-
uration with cloﬁbrate having the greatest eﬀect and gem-
ﬁbrozil the least eﬀect [25]. In the World Health Organi-
zation (WHO) cloﬁbrate primary prevention study, the ex-
cess mortality in the cloﬁbrate group was due to a 33%
increase in noncardiovascular mortality, including malig-
nancy, postcholecyctomy complications, and pancreatitis
[18]. Cholelithiasis and cholecystectomy rates were also
higher in the Coronary Drug Project cloﬁbrate arm and with
gemﬁbrozil in the Helsinki Heart Study [17, 22]. In FIELD,
although the rate of cholecystectomy was not reported, more
cases of pancreatitis occurred in those receiving fenoﬁbrate
than placebo [40 (0.8%) versus 23 (0.5%), resp.; P = .31]
[11].
Therefore, for a number of eﬃcacy and safety reasons, ﬁ-
bratesshouldnotbeusedindiscriminatelyforcardiovascular
risk reduction. Furthermore, the role of ﬁbrates for cardio-
vascular prevention is not clearly deﬁned in the era of statin
therapy. Statins are ﬁrst-line therapy based on an extensive
record of safety and eﬃcacy in over 100,000 subjects to date,
regardless of LDL or HDL level [30]. Whether adding a ﬁ-
brate to statin therapy will reduce cardiovascular risk beyond
that of statin monotherapy remains to be proven in the Ac-
tion to Control Cardiovascular Risk in Diabetes (ACCORD)
study to be completed in 2010 [31]. This trial will also eval-
uate the safety of adding fenoﬁbrate to simvastatin therapy.
In a corrected post hoc analysis of FIELD, when adjusting for
the use of other lipid-lowering therapy, fenoﬁbrate reduced
major cardiovascular events by only 4% (95% CI −7 to 14,6 PPAR Research
P = .45) [32]. It should be noted that this degree of risk
reduction could simply be achieved by doubling the statin
dose, which would lower LDL an additional 5–7% [33].
Safety is the other main concern with combination
ﬁbrate-statin therapy. There is consistent evidence that ﬁ-
brates increase the risk of myopathy when used in combina-
tion with currently marketed statins. Fenoﬁbrate is consid-
ered the ﬁbrate of choice for those requiring statin therapy
due to the lesser impact of fenoﬁbrate on statin pharmacoki-
netics compared with gemﬁbrozil [25]. The risk of myopa-
thy with gemﬁbrozil-statin therapy is about 30-fold higher
than for fenoﬁbrate-statin therapy [34]. When a gemﬁbrozil-
statin combination is used in the highest-risk patients who
are most likely to beneﬁt (age ≥ 65 years with CHD and dia-
betes) the risk of rhabdomyolysis is almost 50-fold higher (1
in 484) than for statin monotherapy in unselected hospital-
ized patients [35].
Until more data become available, the addition of a ﬁ-
brate to statin therapy should be reserved for patients at the
highest near-term risk of cardiovascular death with elevated
triglycerides and/or low HDL. In these patients, the reduc-
tion in deaths from cardiovascular causes by far outweighs
any excess risk of death from noncardiovascular causes or of
serious adverse events. This would include patients identi-
ﬁed as very high risk by the U.S. National Cholesterol Educa-
tion Program Adult Treatment Panel, such as those with car-
diovascular disease with additional high risk characteristics,
such as diabetes or metabolic syndrome, smokers, multiple
risk factors, or those with diabetes and multiple poorly con-
trolled risk factors, including smoking [30]. However, given
the modest incremental beneﬁt beyond that expected from
its degree of LDL-lowering, the FIELD results may dampen
enthusiasm for combination fenoﬁbrate-statin therapy for
the treatment dyslipidemia in the absence of severe hyper-
triglyceridemia (deﬁned as ≥500mg/dl [36]).
Eventhoughgemﬁbrozilmaybemoreeﬀectiveforreduc-
ing cardiovascularevents than fenoﬁbrate,at leastwhenused
asmonotherapy,concomitantuseofgemﬁbrozilwithastatin
carries a much higher risk of myopathy than the fenoﬁbrate
statin combination. There were no cases of rhabdomyoly-
sis in the 1000 subjects receiving both fenoﬁbrate and statin
therapy in FIELD [11]. Whether gemﬁbrozil is actually safer
than fenoﬁbrate would depend on the results of a head-to-
head trial, although such a trial is unlikely to be performed.
Marine omega-3 oils might prove to be a superior choice
in terms of safety for the treatment of severe hypertriglyc-
eridemia in patients requiring a statin therapy, especially in
patients with impaired renal function since both fenoﬁbrate
and gemﬁbrozil have signiﬁcant renal excretion [25]. Doses
of omega-3 fatty acids of 3.4 grams or greater oﬀer similar
triglyceride-loweringeﬃcacytoﬁbratesinsomepatientpop-
ulations [37]. Although yet to be proven in a clinical trial in
a population without high ﬁsh consumption, omega-3 fatty
acids may also provide the added beneﬁt of sudden death
prevention and lower risk of total mortality [38].
Fibrates may also be reasonably considered for cardio-
vascular prevention in statin intolerant patients with dyslipi-
demia (for which gemﬁbrozil may be preferred). Fenoﬁbrate
has been shown to produce incremental improvements in
triglycerides, HDL, and non-high-density lipoprotein (non-
HDL) cholesterol used in combination with ezetimibe [39].
Fibrates are considered ﬁrst-line drug therapy for the treat-
ment of severe hypertriglyceridemia to prevent pancreatitis.
Although clinical trials have not been performed to establish
themorbidityandmortalitybeneﬁtsoftreatingseverehyper-
triglyceridemia, ﬁbrates are very eﬀective for treating triglyc-
eride levels >500mg/dl [36]. It is not clear whether the small
increase in pancreatitis risk with fenoﬁbrate will increase the
overall risk of pancreatitis in severely hypertriglyceridemic
patients.
3. PPAR-γ AGONISTS: THIAZOLIDINEDIONES
Four large trials of TZDs with cardiovascular endpoints have
now been reported. The ﬁrst cardiovascular endpoint trial,
the PROspective pioglitAzone Clinical Trial In macroVascu-
lar Events (PROACTIVE) study, enrolled over 5200 subjects
with both diabetes and clinical CHD or peripheral arterial
disease [40]. When acute coronary syndromes, revascular-
ization, and amputation were included along with the ac-
cepted “hard” endpoints of nonfatal myocardial infarction,
stroke, and total mortality in the primary endpoint, piogli-
tazone was not of signiﬁcant beneﬁt [HR 0.90% (95% CI
0.80 to 1.02), P = .095] (Table 3). However, for the secondary
endpoint of nonfatal myocardial infarction, stroke, and total
mortality, those receiving pioglitazone experienced a signif-
icant 16% reduction over the 3 years of the trial. The 16%
reduction in ischemic events and death appears to be bet-
ter than expected for the degree of lipid changes (Figure 1).
The approximate 9% decrease in risk from the increase in
HDL with pioglitazone might have been counterbalanced
by the 2% increase in risk due to the 2% increase in LDL
(Table 4) for a net expected cardiovascular risk reduction of
7%. Based on a meta-analysis, the 0.5% absolute decrease in
hemoglobin A1c (HbA1c) would be expected to result in a
6-7% decrease in cardiovascular risk [41]. Thus, it appears
that the reduction in cardiovascular risk observed with pi-
oglitazone is similar to the expected 14% reduction from the
combined changes in HDL, LDL, and HbA1C.
The US Food and Drug Administration recently required
that a “black box” warning for congestive heart failure be
placed on the labels of both currently available TZDs, pi-
oglitazone and rosiglitazone [42]. TZDs, as a class, are well
known to increase ﬂuid retention through unknown mech-
anisms, which appear to be the primary contributor to the
increased risk of congestive heart failure with TZDs [43, 44].
Fluid retention or edema occurs in 3–5% of patients with di-
abetesstartedonTZDsandupto15%ofpatientstreatedwith
both TZDs and insulin [45, 46]. In PROactive, more cases
of congestive heart failure occurred with pioglitazone (11%)
compared to placebo (8%; P<. 0001). The additional 56
cases of heart failure in the pioglitazone group directly coun-
terbalanced the 55 fewer primary event endpoints (exclud-
ing silent myocardial infarctions). Despite 25 of the 47 cases
of fatal heart failure occurring in the pioglitazone group,
those receiving pioglitazone still had fewer deaths, 177 ver-
sus 186, although this was not statistically signiﬁcant. In the
Figure 1,whentheincreasedriskofcongestiveheartfailureisJennifer G. Robinson 7
Table 3: Selected morbidity and mortality outcomes in large, long-term trials of PPAR-γ agonists. CHD = coronary heart disease, CVD =
cardiovascular disease, MI = myocardial infarction, NR = not reported.
Event rates
PROACTIVE [40]
Nonfatal MI Stroke
Nonfatal
Total mortality Hospitalized CHF Cancer Mean F/U 2.9 years MI/stroke/
Type 2 diabetes anydeath
Placebo
5.5% 4.1% 13.6% 7.1% 4% 4%
N = 2633
Pioglitazone
4.6% 3.3% 11.6% 6.8% 6% 4%
N = 2605
Hazard ratio
(95% CI)
0.83
(0.65–1.06)
0.81
(0.61–1.07)
0.84
0.96
(0.78–1.18)
RR∗ 1.5
P = .007
RR∗ 1.0 (0.72–0.98)
P=.03
DREAM [50]
All MI CVDdeath Stroke
Nonfatal
MI/stroke/
CVDdeath
Total mortality CHF Diabetes Median F/U 3.0 years
Glucose intolerance
Placebo
0.3% 0.4% 0.2% 0.9% 1.3% 0.1% 25%
N = 2634
Rosiglitazone
0.6% 0.5% 0.3% 1.2% 1.1% 0.5% 10.6%
N = 2365
Hazard ratio
(95% CI)
1.66 1.20 1.39 1.39 0.91 7.03 0.38
(0.73–3.80) (0.52–2.77) (0.44–4.40) (0.55–1.49) (1.60–30.9) (0.33–0.44)
P=.2 P = .7 P=.6 P=.2 P = .7 P=.01 P<. 0001
ADOPT [49]
AllMI Stroke MI/stroke CHF Median F/U 4.0 years
Type 2 diabetes
Metformin (M)
1.5% 1.3% 2.8% 1.3% N = 1454
38% drop-out rate
Glyburide (G)
1.2% 1.2% 2.4% 0.6% N = 1441
37% drop-out rate
Rosiglitazone (R)
1.8% 1.1% 2.9% 1.5% N = 1456
44% drop-out rate
Hazard ratio
(95% CI)
Rv e r s u sM Rv e r s u sM Rv e r s u sM
Rv e r s u sM1 . 2 2
(0.66–2.26, P=.52)
Rv e r s u sG2 . 2 0
(1.01–4.79, P=.05)
RR∗ 1.2 RR∗ 0.85 RR∗ 1.03
Rv e r s u sG Rv e r s u sG Rv e r s u sG
RR∗ 1.5 RR∗ 0.92 RR∗ 1.21
RECORD [51] interim
All MI CVDdeath
Nonfatal
MI/stroke/
CVDdeath
Total mortality CHF analysis
Mean F/U 3.75 years
Type 2 diabetes
Metformin/sulfonylurea
1.8% 2.1% 5.1% 3.6% 1.0% N = 2227
10% drop-out rate
Rosiglitazone
2.2% 1.7% 4.9% 3.3% 2.1%
added on to
metformin/sulfonylurea
N = 2220
10% drop-out rate8 PPAR Research
Table 3: Continued.
Event rates
Hazard ratio
(95% CI)
1.23 0.80 0.96 0.93 2.15
(0.81–1.86) (0.52–1.24) (0.74–1.24) (0.67–1.27) (1.30–3.57)
P=.34 P=.32 P=.74 P=.63 P=.003
∗RR = Crude relative risk; hazard ratio not reported.
Table 4: Selected laboratory data from endpoint trials of PPAR-γ agonists.
Mean baseline level Diﬀerence between treatment groups
[mg/dL (mmol/L)] End-of-study
PROACTIVE [40]
HbA1c 7.9% −6%
LDL 112 (2.9) 2%
HDL 42 (1.1) 9%
Triglycerides 159 (1.8) −13%
DREAM [50] HbA1c and lipids not reported
ADOPT [49] Median baseline level Rosiglitazone versus Rosiglitazone versus
[mg/dL (mmol/L)] Metformin Glyburide
Glycated Hgb 7.4% −2% −6%
Total cholesterol 204 (5.28) NR NR
LDL 120 (3.11) 8% 5%
HDL 47 (1.22) 3% 6%
Triglycerides 161 (1.82) −2% −5%
RECORD [51, 77] Mean baseline level
[mg/dL (mmol/L)]
Glycated Hgb 7.9% NR
LDL 127 (3.29) NR
HDL 46 (1.20) NR
Triglycerides 202 (2.28) NR
combined with the reduction in nonfatal MI, stroke, and
death, pioglitazone performs worse than expected based on
the lipid changes and appears to obviate the reduction in
risk from improved glucose control. Taken together, these
ﬁndings suggest that overall cardiovascular prevention is not
a signiﬁcant beneﬁt of pioglitazone. There is a suggestion,
however, that pioglitazone may have a net cardiovascular
beneﬁtoveraperiodasshortat3yearsifamethodtoprevent
the ﬂuid retention of TZDs is found.
On the other hand, rosiglitazone may not provide any
clear cardiovascular beneﬁts, and indeed there is concern
that rosiglitazone may increase CHD risk. In a recent meta-
analysis of 42 trials of at least 24 weeks duration, Nissen and
Wolski found that those receiving rosiglitazone had a 43%
higher risk of myocardial infarction and a 64% higher risk
of cardiovascular death [47]. However, substantial method-
ologic limitations prevent deﬁnitive conclusions from being
drawn regarding the safety of rosiglitazone from this analy-
sis [48]. In the 3 large, long-term trials of rosiglitazone re-
ported to date, ﬁndings have been mixed regarding its bene-
ﬁts [49–51]. Two trials were performed in subjects with type
2 diabetes, and 1trial wasfordiabetes prevention. Inall3tri-
als, nonsigniﬁcant increases in nonfatal and fatal myocardial
infarctions occurred in the rosiglitazone compared to con-
trol groups (Table 3). However, in all 3 trials, total mortal-
ity was lower in the rosiglitazone-treated groups, albeit again
notachievingstatisticalsigniﬁcance.Sincemyocardialinfarc-
tion, stroke, and death rates were low over the 3-4 years of
observation in these trials, they were not powered to de-
tect a diﬀerence in macrovascular events or mortality. As
expected, all trials observed an increase in congestive heart
failure, which further exacerbated the lack of cardiovascular
beneﬁt for rosiglitazone compared to control.
BothcurrentlyapprovedTZDslowerHbA1cby1%when
used alone or in combination in patients with poorly con-
trolled diabetes [45, 46]. Both TZDs modify lipids to a
lesser degree than ﬁbrates. Rosiglitazone, however, appears
to increase HDL half as much and LDL twice as much as
pioglitazone [52]. The only TZD endpoint trial reporting
both baseline and end-of-study laboratory values was the
AD i a b e t e sO u t c o m eP r o g r e s s i o nT r i a l( A D O P T ) ,c o m p a r -
ing rosiglitazone to metformin or glyburide [Table 4][ 49].
About 35% of subjects dropped out of the rosiglitazone and
metformin groups during the trial, and over 45% dropped
out of the glyburide group, limiting conclusions that can be
drawn regarding the relative cardiovascular eﬀects of theseJennifer G. Robinson 9
agents. Acknowledging this limitation, in Figure 1, rosigli-
tazone performed about as well in terms of a reduction in
cardiovascular events, even if congestive heart failure events
were included, as would be expected from the lipid changes
when compared to metformin. It is perhaps surprising that
rosiglitazone performed much worse than expected when
compared to glyburide. An analysis of a large insurance data-
base suggested that the risk of cardiovascular events with
rosiglitazone was higher than with metformin, but lower
than with sulfonylureas [53]. Another analysis of a large Vet-
erans Health Administration database, however, suggested
no diﬀerences in overall mortality for those receiving met-
formin, sulfonylureas, or TZDs [54].
Only baseline lipids were reported for the Rosiglita-
zone Evaluated for Cardiac Outcomes and Regulation of
Glycaemia in Diabetes (RECORD) trial [51]. Extrapolating
the relative degree of lipid changes observed in a head-to-
head comparison of rosiglitazone to pioglitazone [52], it can
be seen in Figure 1 that the cardiovascular event rates in
RECORD was about what was expected from the extrapo-
lated lipid changes (4.5% increase in HDL and 4% increase
in LDL, or a 1% expected decrease in cardiovascular risk).
Rosiglitazone has a net cardiovascular harm when congestive
heart failure is added to myocardial infarctions and strokes
(131 events versus 113 events, crude relative risk 1.16). Un-
fortunately, neither lipids nor HbA1c were reported for the
Diabetes REduction Assessment with ramipril and rosiglita-
zone Medication (DREAM) trial, which evaluated the eﬀect
of rosiglitazone for the prevention of type 2 diabetes in 5269
adults at high risk on the basis of impaired fasting glucose
and/or impaired glucose tolerance [50].
Taken as a whole, these ﬁndings may suggest that rosigli-
tazone has adverse eﬀects on both heart failure and non-
heart failure cardiovascular events that outweigh any bene-
ﬁcial changes in HbA1c. It is possible that a period of treat-
mentlongerthan3-4yearsisneededtodemonstrateareduc-
tion in cardiovascular events, and ongoing trials of rosigli-
tazone will help to address this question, the Bypass An-
gioplasty Revascularization Investigation 2 Diabetes (BARI
2D) Trial, Veterans Aﬀairs Diabetes Trial (VADT), and AC-
CORD [31, 55, 56]. However, it should be noted that piogli-
tazone already appears to perform better than expected from
its lipid-modifying eﬀects over a period of 3 years. Pioglita-
zonehasbeenshowntoreduceinﬂammationadditivetothat
of simvastatin therapy, an eﬀect that appears to be related
to improvements in insulin resistance [57]. As for ﬁbrates,
it remains to be established whether adding pioglitazone to
statin therapy will provide additional cardiovascular risk re-
duction.Somedataregardingthisquestionmayemergefrom
ACCORD if pioglitazone replaces rosiglitazone as part of the
diabetes management regimen [58].
Safety concerns in addition to congestive heart failure
have emerged for TZDs. Both pioglitazone and rosiglitazone
have an increased fracture risk [46, 59]. This may inﬂuence
net beneﬁts in women, and in older men, with long-term
u s e .C a n c e rr a t e sw e r er e p o r t e do n l yf o rP R O a c t i v ea m o n g
the longer-term TZD trials. Rates were similar in both treat-
mentgroups,withtheexceptionofbladdercancerwhichwas
more frequent in the pioglitazone group [40]. Once bladder
cancers occurring within the ﬁrst year of the study were ex-
cluded from the analysis, 6 of the 9 cases were in the piogli-
tazone group and the imbalance was not felt to be related to
pioglitazone treatment by the investigators. There have not
yet been suﬃcient long-term follow-up studies to conﬁrm if
this ﬁnding is other than chance. Given the short duration
of the study, this ﬁnding could eventually be of importance
since rodents have shown an excess of bladder cancers with
pioglitazone despite in vitro antineoplastic eﬀects [45, 60].
In sum, PROACTIVE demonstrated that pioglitazone
canbeusedwithoutanetexcessofseriousadversecardiovas-
cular eﬀects to manage hyperglycemia in a population of pa-
tients with diabetes and advanced cardiovascular disease. Pi-
ogltiazone may have beneﬁts other than cardiovascular pre-
vention, including its use in combination with other agents
to control glucose and prevent microvascular events in prop-
erly selected patients. Piogltiazone should be used with cau-
tion in patients with New York Heart Association (NYHA)
functional class 1 and 2 heart failure and are contraindicated
in patients with class 3 or 4 heart failure. [43]. There were
consistently fewer atherosclerotic CHD and stroke events in
those who received pioglitazone who had history of either
CHD or stroke at baseline and the risk of congestive heart
failure with pioglitazone was similar in those with and with-
out CHD and with and without stroke [61, 62].
However, in PROactive, in addition to hospitalized and
unhospitalized heart failure, 1 out of 10 patients experienced
discomfort and concern from ﬂuid retention not requiring
hospitalization [221 excess cases of edema without heart fail-
ure, number needed to treat (NNT) = 12]. These ﬁndings
conﬁrm that pioglitazone should remain second- or third-
line therapy for the treatment of diabetes in patients [63].
Given the suggestion that rosiglitazone may carry an excess
ofcardiovasculareventsbeyondtheexpectedincreaseincon-
gestive heart failure, until more data from long-term studies
are available, rosiglitazone should be avoided and pioglita-
zoneusedpreferentiallyforglucosemanagementifindicated.
Long-term event trials will be needed necessary to establish
both eﬃcacy and safety of any future PPAR-γ agonists, espe-
cially in light of the earlier withdrawal of troglitazone due to
excess hepatic toxicity the emerged in postmarketing experi-
ence.
4. DUAL AGONISTS
The dual PPAR-α/γ agonists, or glitazars, developed to date
display signiﬁcantly higher PPAR-γ aﬃnity than PPAR-α
aﬃnity, although their aﬃnity for PPAR-α is higher than
that of clinically used ﬁbrates [64]. The dual PPAR-α/γ ag-
onists have also been a disappointment in terms of cardio-
vascular prevention. Muraglitazar came the furthest along in
development, and appears to have compounded the worst
properties of the PPAR-α and PPAR-γ agonists used sepa-
rately. In another review by Nissen et al. of Phase 2 and 3
trials ranging from 24 weeks to 2 years in duration, muragli-
tazar had a more than 2-fold incidence of CHD and stroke
over placebo [65]. The adverse impact on cardiovascular
risk occurred despite superior glucose-lowering and HDL-
raising over pioglitazone [66]. Despite some suggestion that10 PPAR Research
fenoﬁbrate may attenuate ﬂuid retention from rosiglitazone
[67], ﬂuid retention with muraglitazar occurred at a rate
signiﬁcantly higher than placebo. Development of tesagli-
tazar, another dual PPAR-α/γ agonist, was also terminated
in Phase 3 development due to impairments of renal func-
tion [25, 68]. Bezaﬁbrate is a pan-PPAR activator [15]a n d
was associated with increased cardiovascular mortality in the
Bezaﬁbrate Infarction Prevention study, despite a large in-
crease in HDL and improvements in LDL and triglyceride
levels [10]. A number of other glitazars, including ragagli-
tazar, farglitazar, and imiglitazar, some with even more im-
pressive eﬀects on HDL and LDL than muraglitazar, have
been terminated in late stage clinical trials due to safety con-
cerns including carcinogenic eﬀects, liver function test ab-
normalities, anemia, and decreased blood counts in part due
to fatty inﬁltration of the bone marrow, in addition to ﬂuid
retention [64, 69].
5. PPAR AGONISTS AND CARDIOVASCULAR
PREVENTION—WHAT NEXT?
In regard to pioglitazone, and perhaps other drugs activat-
ing PPAR-γ, if the mechanism underlying excess ﬂuid reten-
tion can be addressed, the beneﬁts should begin to outweigh
adverse eﬀects when used in high-risk populations. In the
absence of such atherapeutic advance, a gene strongly pre-
dicting ﬂuid overload with PPAR-γ and dual PPAR α/γ has
been identiﬁed. If replicated in larger populations, this ge-
netic polymorphism may identify which patients are least
likely to experience ﬂuid overload, which should result in a
net cardiovascular beneﬁt, at least for pioglitazone [70].
Research into other dual PPARα/γ agonists with an im-
proved safety margin is ongoing [64]. Selective modulation
has been described for both PPAR-α [71] and PPAR-γ [72]
and could explain the variation in biologic activity of vari-
ousPPARligandswithinthesamepharmacologicclass.Since
PPARs control numerous genes, beyond those inﬂuencing
lipid and glucose metabolism, it is not surprising that the di-
verse origins adverse eﬀects with PPAR agonists appear to be
compound-speciﬁc,ratherthanaresultofactivationofmore
than one PPAR. The selective PPAR modulator (SPPARM)
approach has been proposed as a method for developing lig-
ands that diﬀerentially regulate genes speciﬁc for desirable
biological eﬀects but devoid of adverse eﬀects. Several selec-
tive dual PPAR agonists in development do not appear to
have adverse eﬀects on fat accumulation and edema [64].
Metaglidasen is one such compound [73]. To further en-
hance safety, partial selective agonists appear to be more de-
sirable than potent agonists. For example, potent PPAR-α ac-
tivators may increase insulin resistance, induce cardiac hy-
pertrophy, and reduce cardiac function [74]. Since gemﬁr-
brozil appears to be of greater beneﬁt for cardiovascular pre-
vention while fenoﬁbrate appears to be safer, a potentially
fruitful avenue of investigation may be using the SPPARM
approach to characterize the diﬀerential patterns of gene ac-
tivation in various tissues for these 2 drugs.
The more recently discovered PPAR-δ has also been
found to be a powerful regulator of fatty acid catabolism and
energy homeostasis [6]. PPAR-δ agonism has been shown
to prevent weight gain, dyslipidemia, and fatty liver in ani-
mals fed high-calorie diets [7]. A synthetic PPAR-δ agonist,
GW501516, has been shown to modestly increase HDL-C
levels and enhance serum fat clearance in an early human
study [75]. Pan PPAR-α, δ, γ agonists have the potential to
address multiple aspects of the metabolic syndrome with a
single medication. One such pan-agonist, netoglitazone, has
improved cell and tissue selectivity and is undergoing Phase
II and III trials [73].
As our understanding of the eﬀects modulating genetic
expression in a variety of tissues continues to develop, safe
and eﬀective drugs to prevent the complications of obe-
sity and diabetes should emerge. Clearly, all such drugs will
need to undergo rigorous evaluation in long-term morbid-
ity/mortality trials early in their development. Appropriate
composite endpoints in these trials will be needed to evalu-
ate the net beneﬁts of PPAR activating drugs.
REFERENCES
[1] R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and
the complex journey to obesity,” Journal of Nature Medicine,
vol. 10, no. 4, pp. 355–361, 2004.
[2] B. V. Howard, B. L. Rodriguez, P. H. Bennett, et al., “Preven-
tion conference vi: diabetes and cardiovascular disease: writ-
ing group I: epidemiology,” Circulation, vol. 105, no. 18, pp.
e132–137, 2002.
[3] S. M. Grundy, “Small LDL, atherogenic dyslipidemia, and the
metabolicsyndrome,”Circulation,vol.95,no.1,pp.1–4,1997.
[4] P. Lefebvre, G. Chinetti, J.-C. Fruchart, and B. Staels, “Sorting
out the roles of PPAR γ in energy metabolism and vascular
homeostasis,” Journal of Clinical Investigation, vol. 116, no. 3,
pp. 571–580, 2006.
[5] R. K. Semple, V. K. K. Chatterjee, and S. O’Rahilly, “PPARα
and human metabolic disease,” Journal of Clinical Investiga-
tion, vol. 116, no. 3, pp. 581–589, 2006.
[6] G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ:ad a g g e r
in the heart of the metabolic syndrome,” Journal of Clinical
Investigation, vol. 116, no. 3, pp. 590–597, 2006.
[7] Y.-X. Wang, C.-H. Lee, S. Tiep, et al., “Peroxisome-
proliferator-activated receptor delta activates fat metabolism
to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.
[8] H. B. Rubins, S. J. Robins, D. Collins, et al., “Gemﬁbrozil for
the secondary prevention of coronary heart disease in men
with low levels of high-density lipoprotein cholesterol,” New
EnglandJournalofMedicine,vol.341,no.6,pp.410–418,1999.
[9] M. H. Frick, O. Elo, and K. Haapa, “Helsinki Heart Study:
Primary-prevention trial with gemﬁbrozil in middle-aged
menwithdyslipidemia.safetyoftreatment,changesinriskfac-
tors, and incidence of coronary heart disease,” New England
Journal of Medicine, vol. 317, no. 20, pp. 1237–1245, 1987.
[10] S. Behar, D. Brunner, E. Kaplinsky, L. Mandelzweig, and M.
Benderly, “Secondary prevention by raising HDL cholesterol
andreducingtriglyceridesinpatientswithcoronaryarterydis-
ease: the bezaﬁbrate infarction prevention (BIP) study,” Circu-
lation, vol. 102, no. 1, pp. 21–27, 2000.
[11] A. Keech, R. J. Simes, P. Parter, et al., “Eﬀects of long-term
fenoﬁbrate therapy on cardiovascular events in 9795 people
with type 2 diabetes mellitus (the FIELD study): randomised
controlled trial,” Lancet, vol. 366, no. 9500, pp. 1849–1861,
2005.Jennifer G. Robinson 11
[12] S. J. Robins, D. Collins, J. T. Wittes, et al., “Relation of gemﬁ-
brozil treatment and lipid levels with major coronary events.
VA-HIT: a randomized controlled trial,” Journal of the Ameri-
can Medical Association, vol. 285, no. 12, pp. 1585–1591, 2001.
[13] J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott,
“Pleiotropic eﬀects of statins: beneﬁt beyond cholesterol re-
duction? a meta-regression analysis,” Journal of the American
College of Cardiology, vol. 46, no. 10, pp. 1855–1862, 2005.
[14] D. J. Gordon, J. L. Probstﬁeld, R. J. Garrison, et al., “High-
density lipoprotein cholesterol and cardiovascular disease.
four prospective american studies,” Circulation, vol. 79, no. 1,
pp. 8–15, 89.
[15] A. Tenenbaum, M. Motro, and E. Z. Fisman, “Dual and
pan-peroxisome proliferator-activated receptors (PPAR) co-
agonism: the bezaﬁbrate lessons,” Cardiovascular Diabetology,
vol. 4, 2005.
[16] G. Steiner, A. Hamsten, J. Hosking, et al., “Eﬀe cto ff e n o ﬁ b ra t e
on progression of coronary-artery disease in type 2 diabetes:
the diabetes atherosclerosis intervention study, a randomised
study,” Lancet, vol. 357, no. 9260, pp. 905–910, 2001.
[17] Coronary Drug Project, “Cloﬁbrate and niacin in coro-
nary heart disease,” Journal of American Medical Association,
vol. 231, no. 4, pp. 360–380, 1975.
[18] M. Oliver, “A co-operative trial in the primary prevention of
ischaemic heart disease using cloﬁbrate. report from the com-
mitteeofprincipalinvestigators,”BritishHeartJournal,vol.40,
no. 10, pp. 1069–1118, 1978.
[19] M. H. Frick, O. P. Heinonen, J. K. Huttunen, P. Koskinen, M.
M¨ antt¨ ari, and V. Manninen, “Eﬃcacy of gemﬁbrozil in dys-
lipidaemic subjects with suspected heart disease. an ancillary
study in the Helsinki Heart Study frame population,” Annals
of Medicine, vol. 25, no. 1, pp. 41–45, 1993.
[20] C. Baigent, A. Keech, P. M. Kearney, et al., “Eﬃcacy and safety
of cholesterol-lowering treatment: prospective meta-analysis
of data from 90,056 participants in 14 randomised trials of
statins,” Lancet, vol. 366, no. 9493, pp. 1267–1278, 2005.
[21] L. Tenkanen, M. M¨ antt¨ ari, P. T. Kovanen, H. Virkkunen, and
V. Manninen, “Gemﬁbrozil in the treatment of dyslipidemia:
an 18-year mortality follow-up of the Helsinki Heart Study,”
Archives of Internal Medicine, vol. 166, no. 7, pp. 743–748,
2006.
[22] J. K. Huttunen, O. P. Heinonen, V. Manninen, et al., “The
helsinki heart study: an 8.5-year safety and mortality follow-
up,” Journal of Internal Medicine, vol. 235, no. 1, pp. 31–39,
1994.
[23] H. B. Rubins, S. J. Robins, D. Collins, et al., “Diabetes, plasma
insulin, and cardiovascular disease: subgroup analysis from
t h eD e p a r t m e n to fV e t e r a n sA ﬀairs High-density Lipoprotein
Intervention Trial (VA-HIT),” Archives of Internal Medicine,
vol. 162, no. 22, pp. 2597–2604, 2002.
[24] S. Westphal, J. Dierkes, and C. Luley, “Eﬀects of fenoﬁbrate
and gemﬁbrozil on plasma homocysteine,” Lancet, vol. 358,
no. 9275, pp. 39–40, 2001.
[25] M. H. Davidson, A. Armani, J. M. McKenney, and T. A. Ja-
cobson,“Safety considerations withﬁbrate therapy,” American
JournalofCardiology, vol.99, no.6,suppl.1,pp.S3–S18, 2007.
[26] G. Luc, N. Jacob, M. Bouly, J.-C. Fruchart, B. Staels, and P. Gi-
ral, “Fenoﬁbrate increases homocystinemia througha PPARα-
mediated mechanism,” Journal of Cardiovascular Pharmacol-
ogy, vol. 43, no. 3, pp. 452–453, 2004.
[27] O. Mayer Jr., J. ˇ Simon, L. Holubec, R. Pikner, and I. ˇ Subrt,
“Fenoﬁbrate-induced hyperhomocysteinemia may be pre-
vented by folate co-administration,” European Journal of Clin-
ical Pharmacology, vol. 59, no. 5-6, pp. 367–371, 2003.
[28] S. Kaul, A. A. Zadeh, and P. K. Shah, “Homocysteine hy-
pothesis for atherothrombotic cardiovascular disease. not val-
idated,” Journal of the American College of Cardiology, vol. 48,
no. 5, pp. 914–923, 2006.
[29] C. Hottelart, N. El Esper, F. Rose, J. M. Achard, and A.
Fournier, “Fenoﬁbrate increases creatininemia by increasing
metabolic production of creatinine,” Nephron,v o l .9 2 ,n o .3 ,
pp. 536–541, 2002.
[30] S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz, et al., “Im-
plications of recent clinical trials for the National Cholesterol
EducationProgramAdultTreatmentpanelIIIguidelines,”Cir-
culation, vol. 110, no. 2, pp. 227–239, 2004.
[31] J. B. Buse, “Action to control cardiovascular risk in diabetes
(ACCORD) trial: design and methods,” American Journal of
Cardiology, vol. 99, no. 12, suppl. 1, pp. S21–S33, 2007.
[32] A. Keech, J. Simes, P. Barter, J. Best, R. Scott, and M.-R. Task-
inen, “Correction to the ﬁeld study report,” Lancet, vol. 368,
no. 9545, p. 1415, 2006.
[33] P.H.Jones,M.H.Davidson,E.A.Stein,etal.,“Comparisonof
the eﬃcacy and safety of rosuvastatin versus atorvastatin, sim-
vastatin,andpravastatinacrossdoses(STELLARtrial),”Amer-
ican Journal of Cardiology, vol. 92, no. 2, pp. 152–160, 2003.
[34] P.H.JonesandM.H.Davidson,“Reportingrateofrhabdomy-
olysiswithfenoﬁbrate+statinversusgemﬁbrozil+anystatin,”
American Journal of Cardiology, vol. 95, no. 1, pp. 120–122,
2005.
[35] D. J. Graham, J. A. Staﬀa, D. Shatin, et al., “Incidence of hospi-
talized rhabdomyolysis in patients treated with lipid-lowering
drugs,” Journal of the American Medical Association, vol. 292,
no. 21, pp. 2585–2590, 2004.
[36] National Cholesterol Education Panel, “Third report of the
National Cholesterol Education Program (NCEP) expert
panel on detection, evaluation, and treatment of high blood
cholesterol in adults (Adult Treatment Panel III) ﬁnal report,”
Circulation, vol. 106, no. 25, pp. 3143–3421, 2002.
[37] J. G. Robinson and N. J. Stone, “Antiatherosclerotic and an-
tithrombotic eﬀects of omega-3 fatty acids,” American Journal
of Cardiology, vol. 98, no. 4, suppl. 1, pp. 39–49, 2006.
[38] C. Wang, W. S. Harris, M. Chung, et al., “N-3 fatty acids from
ﬁsh or ﬁsh-oil supplements, but not α-linolenic acid, beneﬁt
cardiovascular disease outcomes in primary- and secondary-
prevention studies: a systematic review,” American Journal of
Clinical Nutrition, vol. 84, no. 1, pp. 5–17, 2006.
[39] J. M. McKenney, M. Farnier, K.-W. Lo, et al., “Safety and ef-
ﬁcacy of long-term co-administration of fenoﬁbrate and eze-
timibe in patients with mixed hyperlipidemia,” Journal of the
American College of Cardiology, vol. 47, no. 8, pp. 1584–1587,
2006.
[40] J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al., “Sec-
ondary prevention of macrovascular events in patients with
type 2 diabetes in the PROactive Study (PROspective piogli-
tAzone Clinical Trial in macroVascular Events): a randomised
controlled trial,” Lancet, vol. 366, no. 9493, pp. 1279–1289,
2005.
[41] E. Selvin, S. Marinopoulos, G. Berkenblit, et al., “Meta-
analysis: glycosylated hemoglobin and cardiovascular disease
in diabetes mellitus,” Annals of Internal Medicine, vol. 141,
no. 6, pp. 421–431, 2004.12 PPAR Research
[42] J. H. Tanne, “FDA places “black box” warning on antidiabetes
drugs,” British Medical Journal, vol. 334, no. 7606, p. 1237,
2007.
[43] R. W. Nesto, D. Bell, R. O. Bonow, et al., “Thiazolidinedione
use, ﬂuid Retention, and congestive heart failure: a consensus
statement from the American Heart Association and Amer-
ican Diabetes Association,” Circulation, vol. 108, no. 23, pp.
2941–2948, 2003.
[44] H. J. Dargie, P. R. Hildebrandt, G. A. J. Riegger, et al.,
“A randomized, placebo-controlled trial assessing the eﬀects
of rosiglitazone on echocardiographic function and cardiac
status in type 2 diabetic patients with New York Heart
Association Functional Class I or II Heart Failure,” Journal of
the American College of Cardiology, vol. 49, no. 16, pp. 1696–
1704, 2007.
[45] Takeda Pharmaceuticals, “Actos [piogltiazone hydrochlo-
ride] prescribing information,” 2007, http://www.actos.com/
actospro/prescribniginto.aspx.
[46] GlaxoSmithKline, “Avandia (rosiglitazone maleate) [prescrib-
ing information],” 2007, http://us.gsk.com/products/assets/
us avandia.pdf.
[47] S. E. Nissen and K. Wolski, “Eﬀect of rosiglitazone on the
risk of myocardial infarction and death from cardiovascular
causes,” New England Journal of Medicine, vol. 356, no. 24, pp.
2457–2471, 2007.
[48] B. M. Psaty and C. D. Furberg, “Rosiglitazone and cardiovas-
cular risk,” New England Journal of Medicine, vol. 356, no. 24,
pp. 2522–2524, 2007.
[49] S. E. Kahn, S. M. Haﬀner, M. A. Heise, et al., “Glycemic dura-
bilityofrosiglitazone,metformin,orglyburidemonotherapy,”
New England Journal of Medicine, vol. 355, no. 23, pp. 2427–
2443, 2006.
[50] H. C. Gerstein, S. Yusuf, J. Bosch, et al., “Eﬀe cto fr o s i gl i t a z o n e
on the frequency of diabetes in patients with impaired glucose
toleranceorimpairedfastingglucose:arandomisedcontrolled
trial,” Lancet, vol. 368, no. 9541, pp. 1096–1105, 2006.
[51] P. D. Home, S. J. Pocock, H. Beck-Nielsen, et al., “Rosiglita-
zoneevaluatedforcardiovascularoutcomes—aninterimanal-
ysis,” New England Journal of Medicine, vol. 357, no. 1, pp. 28–
38, 2007.
[ 5 2 ] R .B .G o l d b e r g ,D .M .K e n d a l l ,M .A .D e e g ,e ta l . ,“ Ac o m p a r i -
son of lipid and glycemic eﬀects of pioglitazone and rosiglita-
zone in patients with type 2 diabetes and dyslipidemia,” Dia-
betes Care, vol. 28, no. 7, pp. 1547–1554, 2005.
[ 5 3 ]A .T .M c A f e e ,C .K o r o ,J .L a n d o n ,N .Z i y a d e h ,a n dA .M .
Walker, “Coronary heart disease outcomes in patients re-
ceiving antidiabetic agents,” Pharmacoepidemiology and Drug
Safety, vol. 16, no. 7, pp. 711–725, 2007.
[54] K. H. Kahler, M. Rajan, G. G. Rhoads, et al., “Impact of oral
antihyperglycemic therapy on all-cause mortality among pa-
tients with diabetes in the veterans health administration,” Di-
abetes Care, vol. 30, no. 7, pp. 1689–1693, 2007.
[55] M. F. Magee and W. L. Isley, “Rationale, design, and methods
for Glycemic Control in the Bypass Angioplasty Revascular-
ization Investigation 2 Diabetes (BARI 2D) Trial,” American
J o urnalo fCar dio logy, vol. 97,no.12, suppl.1, pp.20–30, 2006.
[56] C.Abraira,W.Duckworth,M.McCarren,etal.,“Designofthe
cooperative study on glycemic control and complications in
d i a b e t e sm e l l i t u styp e2 :v e t e ra n sa ﬀairs diabetes trial,” Journal
of Diabetes and Its Complications, vol. 17, no. 6, pp. 314–322,
2003.
[57] M. Hanefeld, N. Marx, A. Pf¨ utzner, et al., “Anti-inﬂammatory
eﬀects of pioglitazone and/or simvastatin in high cardiovascu-
lar risk patients with elevated high sensitivity C-reactive pro-
tein. the PIOSTAT study,” Journal of the American College of
Cardiology, vol. 49, no. 3, pp. 290–297, 2007.
[58] H. C. Gerstein, M. C. Riddle, D. M. Kendall, et al., “Glycemia
treatment strategies in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial,” American Journal of Cardi-
ology, vol. 99, no. 12, suppl. 1, pp. 34–43, 2007.
[59] T. Hampton, “Diabetes drugs tied to fractures in women,”
Journal of the American Medical Association, vol. 297, no. 15,
p. 1645, 2007.
[60] H. P. Koeﬄer, “Peroxisome proliferator-activated receptor γ
and cancers,” Clinical Cancer Research,v o l .9 ,n o .1I ,p p .1 –
9, 2003.
[61] E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-
Benedetti,I.K.Moules,andA.M.Skene, “Theeﬀectofpiogli-
tazone on recurrent myocardial infarction in 2,445 patients
with type 2 diabetes and previous myocardial infarction. re-
sults from the PROactive (PROactive 05) study,” Journal of the
American College of Cardiology, vol. 49, no. 17, pp. 1772–1780,
2007.
[62] R. Wilcox, M.-G. Bousser, D. J. Betteridge, et al., “Eﬀects of
pioglitazone in patients with type 2 diabetes with or with-
out previous stroke: Results from PROactive (PROspective pi-
oglitAzone Clinical Trial In macroVascular Events 04),” Stroke,
vol. 38, no. 3, pp. 865–873, 2007.
[63] D. M. Nathan, J. B. Buse, M. B. Davidson, et al., “Manage-
ment of hyperglycemia in type 2 diabetes: a consensus algo-
rithm for the initiation and adjustment of therapy. a consen-
sus statement from the american diabetes association and the
european association for the study of diabetes,” Diabetes Care,
vol. 29, no. 8, pp. 1963–1972, 2006.
[64] C. Fi´ evet, J.-C. Fruchart, and B. Staels, “PPARα and PPAR
γ dual agonists for the treatment of type 2 diabetes and
the metabolic syndrome,” Current Opinion in Pharmacology,
vol. 6, no. 6, pp. 606–614, 2006.
[65] S. E. Nissen, K. Wolski, and E. J. Topol, “Eﬀect of muraglitazar
on death and major adverse cardiovascular events in patients
with type 2 diabetes mellitus,” Journal of the American Medical
Association, vol. 294, no. 20, pp. 2581–2586, 2005.
[66] D. M. Kendall, C. J. Rubin, P. Mohideen, et al., “Improve-
ment of glycemic control, triglycerides, and HDL cholesterol
levels with muraglitazar, a dual (α/γ peroxisome proliferator-
activated receptor activator, in patients with type 2 dia-
betes inadequately controlled with metformin monotherapy:
adouble-blind,randomized,pioglitazone-comparativestudy,”
Diabetes Care, vol. 29, no. 5, pp. 1016–1023, 2006.
[67] G. Boden, C. Homko, M. Mozzoli, M. Zhang, K. Kresge, and
P. Cheung, “Combined use of rosiglitazone and fenoﬁbrate in
patients with type 2 diabetes: prevention of ﬂuid retention,”
Diabetes Care, vol. 56, no. 1, pp. 248–255, 2007.
[68] B. Fagerberg, S. Edwards, T. Halmos, et al., “Tesaglitazar, a
noveldualperoxisomeproliferator-activatedreceptorα/γ ago-
nist, dose-dependently improves the metabolic abnormalities
associated with insulin resistance in a non-diabetic popula-
tion,” Diabetologia, vol. 48, no. 9, pp. 1716–1725, 2005.
[ 6 9 ]B .K .S k r u m s a g e r ,K .K .N i e l s e n ,M .M ¨ uller, G. Pabst, P. G.
Drake, and B. Edsberg, “Ragaglitazar: the pharmacokinetics,
pharmacodynamics, and tolerability of a novel dual PPARαJennifer G. Robinson 13
and γ agonist in healthy subjects and patients with type 2 di-
abetes,” Journal of Clinical Pharmacology, vol. 43, no. 11, pp.
1244–1256, 2003.
[ 7 0 ]L .H a n s e n ,C .T .E k s t r ø m ,R .T .Y .P a l a c i o s ,M .A n a n t ,
K. Wassermann, and R. R. Reinhardt, “The Pro12Ala vari-
ant of the PPARG gene is a risk factor for peroxisome
proliferator-activated receptor-γ/α agonist-induced edema in
type 2 diabetic patients,” Journal of Clinical Endocrinology and
Metabolism, vol. 91, no. 9, pp. 3446–3450, 2006.
[71] H. Duez, B. Lefebvre, P. Poulain, et al., “Regulation of human
ApoA-I by gemﬁbrozil and fenoﬁbrate through selective per-
oxisome proliferator-activated receptor α modulation,” Arte-
riosclerosis, Thrombosis, and Vascular Biology,v o l .2 5 ,n o .3 ,
pp. 585–591, 2005.
[72] H. S. Camp, O. Li, S. C. Wise, et al., “Diﬀerential activation of
peroxisome proliferator-activated receptor-γ by troglitazone
and rosiglitazone,” Diabetes, vol. 49, no. 4, pp. 539–547, 2000.
[73] F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O’Connell, “Evo-
lution of peroxisome proliferator-activated receptor agonists,”
Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007.
[74] S.-Y. Park, Y.-R. Cho, B. N. Finck, et al., “Cardiac-speciﬁc
overexpression of peroxisome proliferator-activated receptor-
α causes insulin resistance in heart and liver,” Diabetes, vol. 54,
no. 9, pp. 2514–2524, 2005.
[75] D. L. Sprecher, C. Massien, G. Pearce, et al., “Triglyceride:
high-density lipoprotein cholesterol eﬀects in healthy sub-
jects administered a peroxisome proliferator activated recep-
tor δ agonist,” Arteriosclerosis, Thrombosis, and Vascular Biol-
ogy, vol. 27, no. 2, pp. 359–365, 2007.
[76] V. Manninen, M. O. Elo, M. H. Frick, et al., “Lipid alterations
and decline in the incidence of coronary heart disease in the
helsinki heart study,” Journal of the American Medical Associa-
tion, vol. 260, no. 5, pp. 641–651, 1988.
[77] P. D. Home, S. J. Pocock, H. Beck-Nielsen, et al., “Rosiglita-
zone Evaluated for Cardiac Outcomes and Regulation of Gly-
caemia in Diabetes (RECORD): study design and protocol,”
Diabetologia, vol. 48, no. 9, pp. 1726–1735, 2005.